Cabazitaxel (Jevtana) a novel agent for metastatic castration-resistant prostate cancer

P and T

Volumn 37, Issue 8, 2012, Pages 440-448

  Nightingale Dr , Ginah ^a   Ryu Dr , Jae ^b  

^a Thomas Jeff erson University   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Cabazitaxel; Castrationresistant prostate cancer; Docetaxel resistance; Xrp6258

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CABAZITAXEL; DOCETAXEL; MITOXANTRONE; OCTREO; OCTREOTIDE; PREDNISONE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELLS; DEATH; DIARRHEA; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEBRILE NEUTROPENIA; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE; NEUTROPENIA; OPEN STUDY; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA;

EID: 84865828437     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward, E. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
2. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
3. Uchio EM, Aslan M, Wells CK, et al. Impact of biochemical recurrence in prostate cancer among U.S. veterans. Arch Intern Med 2010;170(15):1390-1395.
4. Antonarakis ES, Trock BJ, Feng Z, et al. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up (Abstract). J Clin Oncol 2009;27(Suppl):15s.
5. D'Amico AV, Cote K, Loffredo M, et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20(23):4567-4573.
6. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
7. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238-244.
8. Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005;96:985-989.
9. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-1159.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
11. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
13. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
14. FDA update. Cabazitaxel, June 18, 2010. Available at: www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm216214.htm. Accessed March 6, 2011.
15. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
16. Rao S, Krauss NE, Heerding JM, et al. 3 ́-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino acids of betatubulin. J Biol Chem 1994;269:3132-3134.
17. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov 2010;9(9):677-678.
18. Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010;5:395-402.
19. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723-730.
20. Jevtana (cabazitaxel) Injection, prescribing information. Bridgewater, N.J.: Sanofi; June 2010. Available at: http://products.sanofi.us/jevtana/jevtana.html. Accessed March 6, 2012.
21. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h IV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19(9):1547-1552.
22. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376(9747):1147-1154.
23. Cabazitaxel at 20 mg/m2 compared to 25 mg/m2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA). March 1, 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01308580. Accessed March 6, 2012.
24. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prostate cancer: Version 1.2011. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed February 1, 2012.
25. Cabazitaxel with radiation and hormone therapy for prostate cancer. January 6, 2012. Available at: http://clinicaltrials.gov/ct2/show/ NCT01420250. Accessed February 1, 2012.
26. Study of cabazitaxel plus bavituximab as second-line chemotherapy for patients with castration-resistant prostate cancer. August 2, 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01335204. Accessed February 1, 2012.
27. Cabazitaxel plus prednisone with octreotide for castration-resistant prostate cancer (CRPC) previously treated with docetaxel. November 9, 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01469338. Accessed February 1, 2012.
28. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). March 1, 2012. Available at: http://clinicaltrials.gov/ct2/show/ NCT01308567. Accessed March 6, 2012.
29. Cabazitaxel-PF induction chemotherapy. November 1, 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01379339. Accessed February 1, 2012.
30. Phase II study of cabazitaxel-XRP6258 in advanced non-small cell lung cancer. January 24, 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01438307. Accessed February 1, 2012.
31. Cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy. January 3, 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01437488. Accessed February 1, 2012.
32. Chemotherapy for patients with gastroesophageal cancers who have progressed after one prior chemo regimen. September 21, 2011. Available at: http://clinicaltrials.gov/ct2/show/NCT01365130. Accessed February 1, 2012.
33. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study. Eur J Cancer 2011;47(7):1037-1045.
34. de Bono JS, Sartor O. Author's reply. Lancet 2011;377:122.
35. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. June 14, 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf. Accessed December 5, 2011.
36. Basch E, Restrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2011;29:4189-4198.
37. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Prevention and treatment of cancer-related infections: Version 2.2011. Available at: www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed February 1, 2012.
38. Manifold C. Cabazitaxel (Jevtana): Another arrow in the prostate cancer quiver. Informulary 2010;3(6):1-2.
39. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: Impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006;12(6):472-478.
40. Red Book. Montvale, N.J.: Thomson Healthcare Inc., 2010.